![]() Unfortunately, however, there is still a large, unmet need for safe and effective treatments for many conditions. Ungar: The field of dermatology has made tremendous advances in the last several years in treating many inflammatory skin diseases. ![]() ![]() Healio: What challenges do you face regularly in practice that keep you up at night? It really highlighted and hammered home the point that AD, and likely other inflammatory skin diseases, have systemic inflammation that can impact the whole body. We assessed these patients using PET/MRI, which can measure active cardiovascular inflammation, and we found that it was elevated in these patients. The third study looked at patients with moderate to severe AD in regard to cardiovascular inflammation. It’s an area of ongoing research that we’re very excited about and interested in, identifying those patients and coming up with treatments targeting that type 2 inflammation in alopecia areata. ![]() We’re beginning to recognize that alopecia areata, for many people, may be a part of the atopic spectrum of diseases. The second study that I was fortunate to be involved in was a profiling study of scalp tissues in alopecia areata where we initially characterized the inflammation seen in the disease and first pointed to type 2 inflammation playing a role in its disease process. That was very significant because it greatly improved our understanding of the disease process in atopic dermatitis how biomarkers in skin and blood were modulated by a very effective targeted treatment. First, we published the first study of biomarkers in using dupilumab (Regeneron Pharmaceuticals/Sanofi-Aventis) to treat moderate-to-severe AD. Three of the studies I’ve participated in have been particularly interesting and exciting to me. My research has focused thus far mostly on atopic dermatitis and alopecia areata, and I have been expanding my efforts into a few other diseases such as seborrheic dermatitis. Ungar: Broadly speaking, my clinical and research focus specialization is in inflammatory skin diseases, as well as how the immunology of the skin relates to the systemic components of the diseases that we study. Healio: Do you have a particular area of dermatology that you enjoy the most? Many different aspects of dermatology came together as really a great fit for me. Ungar: Although dermatology wasn’t the primary specialty on my radar when I entered medical school, as I was exploring different specialties, I came to increasingly realize that it is a great fit for me in terms of the kinds of diseases we treat, the broad range of different patients who suffer from skin conditions and the plentiful and available research opportunities. Healio: How did you come to pursue dermatology as your specialty? Healio spoke with Ungar about how his career began, his research breakthroughs and what is next in dermatology treatment. Ungar is assistant professor of dermatology and director of the Rosacea & Seborrheic Dermatitis Clinic and the Alopecia Center of Excellence at Mount Sinai, in addition to being a member of the Healio Allergy/Asthma Peer Perspective Board. “I was actually born at Mount Sinai as well.” “I went to medical school at Mount Sinai and did my residency there, and now I’m a faculty member,” Ungar told Healio. If you continue to have this issue please contact to Healioīorn and raised in New York City, Benjamin Ungar, MD, considers himself a “lifer” at the Icahn School of Medicine at Mount Sinai.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |